Author Correction: Prostate-specific extracellular vesicles as a novel biomarker in human prostate cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Author Correction: Prostate-specific extracellular vesicles as a novel biomarker in human prostate cancer ; volume:9 ; number:1 ; day:15 ; month:4 ; year:2019 ; pages:1 ; date:12.2019
Scientific reports ; 9, Heft 1 (15.4.2019), 1, 12.2019
- Klassifikation
-
Naturwissenschaften
- Urheber
-
Park, Yong Hyun
Shin, Hyun Woo
Jung, Ae Ryang
Kwon, Oh Sung
Choi, Yeong-Jin
Park, Jaesung
Lee, Ji Youl
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-019-41385-w
- URN
-
urn:nbn:de:101:1-2019042813570680766765
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:49 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Park, Yong Hyun
- Shin, Hyun Woo
- Jung, Ae Ryang
- Kwon, Oh Sung
- Choi, Yeong-Jin
- Park, Jaesung
- Lee, Ji Youl
- SpringerLink (Online service)
Ähnliche Objekte (12)
Biomarkers for prostate cancer: prostate-specific antigen and beyond
Lipidomic profiling of extracellular vesicles derived from prostate and prostate cancer cell lines
Prostate-Specific Antigen Density: A Measurement to Differentiate Benign Hypertrophy of Prostate from Prostate Carcinoma
Any decline in prostate-specific antigen levels identifies survivors scheduled for prostate-specific membrane antigen-directed radioligand therapy
Any decline in prostate‐specific antigen levels identifies survivors scheduled for prostate‐specific membrane antigen‐directed radioligand therapy
Prostate cancer risk prediction based on clinical factors and prostate-specific antigen
Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen
The Additional Value of Free Prostate Specific Antigen to the Battery of Age-Dependent Prostate-Specific Antigen, Prostate-Specific Antigen Density and Velocity
Role of extracellular vesicles in bone-prostate cancer cross-talk
Prostate-specific antigen-based screening: controversy and guidelines
Prostate-specific antigen testing accuracy in community practice
Developing new age-specific prostate-specific antigen thresholds for testing for prostate cancer
Biomarkers for prostate cancer: prostate-specific antigen and beyond
Lipidomic profiling of extracellular vesicles derived from prostate and prostate cancer cell lines
Prostate-Specific Antigen Density: A Measurement to Differentiate Benign Hypertrophy of Prostate from Prostate Carcinoma
Any decline in prostate-specific antigen levels identifies survivors scheduled for prostate-specific membrane antigen-directed radioligand therapy
Any decline in prostate‐specific antigen levels identifies survivors scheduled for prostate‐specific membrane antigen‐directed radioligand therapy
Prostate cancer risk prediction based on clinical factors and prostate-specific antigen
Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen
The Additional Value of Free Prostate Specific Antigen to the Battery of Age-Dependent Prostate-Specific Antigen, Prostate-Specific Antigen Density and Velocity
Role of extracellular vesicles in bone-prostate cancer cross-talk
Prostate-specific antigen-based screening: controversy and guidelines
Prostate-specific antigen testing accuracy in community practice
Developing new age-specific prostate-specific antigen thresholds for testing for prostate cancer
Biomarkers for prostate cancer: prostate-specific antigen and beyond
Lipidomic profiling of extracellular vesicles derived from prostate and prostate cancer cell lines
Prostate-Specific Antigen Density: A Measurement to Differentiate Benign Hypertrophy of Prostate from Prostate Carcinoma
Any decline in prostate-specific antigen levels identifies survivors scheduled for prostate-specific membrane antigen-directed radioligand therapy
Any decline in prostate‐specific antigen levels identifies survivors scheduled for prostate‐specific membrane antigen‐directed radioligand therapy
Prostate cancer risk prediction based on clinical factors and prostate-specific antigen
Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen
The Additional Value of Free Prostate Specific Antigen to the Battery of Age-Dependent Prostate-Specific Antigen, Prostate-Specific Antigen Density and Velocity
Role of extracellular vesicles in bone-prostate cancer cross-talk
Prostate-specific antigen-based screening: controversy and guidelines
Prostate-specific antigen testing accuracy in community practice